A recent study reveals that individuals who stop using popular weight-loss injections like Wegovy and Mounjaro may regain lost weight much more quickly than those who end conventional lifestyle plans.
Findings released in a major medical journal shows that while obese individuals often shed about a fifth of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using these medications should be aware of the risk of rapid weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment weight within about 18 months.
Weighing Treatments
The study, which examined 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
Researchers emphasize that people who lose weight through diet and exercise usually have a less rapid weight regain—around 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Experts propose the way of the jabs accounts for the accelerated weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating far more likely."
A Chronic Issue?
Health authorities suggest the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the therapy is often long-term.
This view is supported by pharmaceutical companies, who note that the results "underscore the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
People who have discontinued the jabs report a sudden resurgence of cravings.
"It was like a switch flipping and I was suddenly extremely hungry," said a patient.
This difficulty is worsened if patients have not developed lasting dietary or behavioural modifications during therapy.
Growing Use
Figures show that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a magic solution and long-term success relies on combined behavioural management.
